Advisory Committees; Filing of Closed Meeting Reports, 38993 [2019-16992]
Download as PDF
38993
Federal Register / Vol. 84, No. 153 / Thursday, August 8, 2019 / Notices
underestimation given that these actions
should not be a burdensome process for
the recordkeeper.
(Comment 3) The commenter opposed
changing the default from ‘‘opt-in’’ to
‘‘opt-out’’ for patients to consent to their
tissue being used for research. Although
simple malformations, such as warts
and tumors, may be useful to labs to
fine-tune their tests, and although many
(even most) patients might be willing to
share this tissue, a significant minority
of Americans hold beliefs about the
human body that would prevent them
from consenting, and all Americans
likely assume that their tissue is
destroyed (burned as medical waste)
after procedures have been performed.
The commenter believes that changing
what happens without changing the
public understanding of what happens
is fundamentally dishonest. The
commenter recognizes that obtaining
consent is time-consuming, particularly
when the patient does not speak English
as a first language, or has other
comprehension issues; however, the
commenter believes no lab has a right to
the tissue of an American citizen for its
private, profit-making use.
(Response) The subject of the
comment deals with sample acquisition,
a step that happens in advance of the
information communicated in this
guidance. Therefore, patient ‘‘opt-in’’
versus ‘‘opt-out’’ is out of scope. This
guidance describes the enforcement
discretion policy FDA uses when
sponsors choose to use de-identified
samples for IVD medical device clinical
trials.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Activity
Number of
recordkeepers
Number of
records per
recordkeeper
Total
annual
records
Average
burden per
recordkeeping
Total
hours
Recordkeeping regarding leftover human specimens that
are not individually identifiable that are used in certain
IVD studies .......................................................................
700
1
700
4
2,800
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Based on a review of the information
collection since our last request for
OMB approval, we have made no
adjustments to our burden estimate.
Dated: August 5, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–17026 Filed 8–7–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FOR FURTHER INFORMATION CONTACT:
Food and Drug Administration
[Docket No. FDA–2019–N–0006]
Advisory Committees; Filing of Closed
Meeting Reports
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing that, as required by the
Federal Advisory Committee Act, the
Agency has filed with the Library of
Congress the annual reports of those
FDA advisory committees that held
closed meetings during fiscal year 2018.
ADDRESSES: Copies are available at the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852, 240–402–7500. You also may
access the docket at https://
www.regulations.gov for the annual
reports of those FDA advisory
committees that held closed meetings
jbell on DSK3GLQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:51 Aug 07, 2019
Jkt 247001
during fiscal year 2018. Insert the
docket number found in brackets in the
heading of this document at https://
www.regulations.gov into the ‘‘Search’’
box, clear filter under Document Type
(left side of screen), and check
‘‘Supporting and Related Material,’’
then Sort By Best Match (from the dropdown menu; top right side of screen),
‘‘ID Number (Z–A)’’ or Sort By Best
Match (from the drop-down menu)
‘‘Title (A–Z),’’ also found in the heading
of this document.
Russell Fortney, Director, Advisory
Committee Oversight and Management
Staff, Food and Drug Administration,
10903 New Hampshire Ave., Silver
Spring, MD 20993–0002, 301–796–1068.
Under
section 10(d) of the Federal Advisory
Committee Act (5 U.S.C. app.) and 21
CFR 14.60(d), FDA has filed with the
Library of Congress the annual reports
for the following FDA advisory
committees that held closed meetings
during the period October 1, 2017,
through September 30, 2018:
SUPPLEMENTARY INFORMATION:
Center for Biologics Evaluation and
Research:
Blood Products Advisory Committee
Vaccine and Related Biological Products
Advisory Committee
Center for Drug Evaluation and
Research:
Joint Meeting of the Anesthetic and
Analgesic Drug Products Advisory
Committee and the Drug Safety and
Risk Management Advisory
Committee
Office of Commissioner
Joint Meeting of the Pediatric Advisory
Committee and the Endocrinologic
and Metabolic Drugs Advisory
Committee
Annual Reports are available for public
inspections between 9 a.m. and 4 p.m.,
Monday through Friday, at:
(1) The Library of Congress, Madison
Building, Newspaper and Current
Periodical Reading Room, 101
Independence Ave. SE, Rm. 133,
Washington, DC; 20540; and
(2) Dockets Management Staff (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852.
Dated: August 5, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–16992 Filed 8–7–19; 8:45 am]
BILLING CODE 4164–01–P
National Center for Toxicological
Research:
Science Board to the National Center for
Toxicological Research
PO 00000
Frm 00067
Fmt 4703
Sfmt 9990
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 84, Number 153 (Thursday, August 8, 2019)]
[Notices]
[Page 38993]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16992]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-0006]
Advisory Committees; Filing of Closed Meeting Reports
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
that, as required by the Federal Advisory Committee Act, the Agency has
filed with the Library of Congress the annual reports of those FDA
advisory committees that held closed meetings during fiscal year 2018.
ADDRESSES: Copies are available at the Dockets Management Staff (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240-402-7500. You also may access the docket at
https://www.regulations.gov for the annual reports of those FDA advisory
committees that held closed meetings during fiscal year 2018. Insert
the docket number found in brackets in the heading of this document at
https://www.regulations.gov into the ``Search'' box, clear filter under
Document Type (left side of screen), and check ``Supporting and Related
Material,'' then Sort By Best Match (from the drop-down menu; top right
side of screen), ``ID Number (Z-A)'' or Sort By Best Match (from the
drop-down menu) ``Title (A-Z),'' also found in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: Russell Fortney, Director, Advisory
Committee Oversight and Management Staff, Food and Drug Administration,
10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-1068.
SUPPLEMENTARY INFORMATION: Under section 10(d) of the Federal Advisory
Committee Act (5 U.S.C. app.) and 21 CFR 14.60(d), FDA has filed with
the Library of Congress the annual reports for the following FDA
advisory committees that held closed meetings during the period October
1, 2017, through September 30, 2018:
Center for Biologics Evaluation and Research:
Blood Products Advisory Committee
Vaccine and Related Biological Products Advisory Committee
National Center for Toxicological Research:
Science Board to the National Center for Toxicological Research
Center for Drug Evaluation and Research:
Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory
Committee and the Drug Safety and Risk Management Advisory Committee
Office of Commissioner
Joint Meeting of the Pediatric Advisory Committee and the
Endocrinologic and Metabolic Drugs Advisory Committee
Annual Reports are available for public inspections between 9 a.m. and
4 p.m., Monday through Friday, at:
(1) The Library of Congress, Madison Building, Newspaper and
Current Periodical Reading Room, 101 Independence Ave. SE, Rm. 133,
Washington, DC; 20540; and
(2) Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Dated: August 5, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-16992 Filed 8-7-19; 8:45 am]
BILLING CODE 4164-01-P